XML 222 R165.htm IDEA: XBRL DOCUMENT v3.25.0.1
Provisions, income tax liabilities and other liabilities - Summary of Non Current Provisions and Other Non-current Liabilities (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure Of Non-current Provisions [line items]          
Provisions € 5,762   € 5,262 € 5,822 € 6,430
Other non-current liabilities [1] 2,334   2,340 519  
Total 8,096   7,602 6,341  
Non-current liabilities 121   164 232  
Increase Decrease Through Reclassification of Business, Other Provisions [2] (154)        
US legal restructuring          
Disclosure Of Non-current Provisions [line items]          
Percentage of capital losses used   33.33%      
Restructuring provisions          
Disclosure Of Non-current Provisions [line items]          
Provisions 799   554 761 524
Increase Decrease Through Reclassification of Business, Other Provisions [2] (21)        
Provisions for other long-term benefits          
Disclosure Of Non-current Provisions [line items]          
Provisions 821   718 844 935
Increase Decrease Through Reclassification of Business, Other Provisions [2] (14)        
Provisions for pensions and other post-employment benefits          
Disclosure Of Non-current Provisions [line items]          
Provisions 1,992   2,214 2,039 2,947
Increase Decrease Through Reclassification of Business, Other Provisions [2] (92)        
Other provisions          
Disclosure Of Non-current Provisions [line items]          
Provisions 2,150   € 1,776 € 2,178 € 2,024
Increase Decrease Through Reclassification of Business, Other Provisions [2] (27)        
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB          
Disclosure Of Non-current Provisions [line items]          
Other non-current liabilities 2,007        
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB | Later than one year and not later than five years          
Disclosure Of Non-current Provisions [line items]          
Other non-current liabilities 1,140        
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB | More than 5 years          
Disclosure Of Non-current Provisions [line items]          
Other non-current liabilities € 2,792        
[1] (a)Includes derivative financial instruments: €121 million as of December 31, 2024, €164 million as of December 31, 2023, €232 million as of December 31,
2022.
The figure as of December 31, 2024 includes €2,007 million for the liability in respect of royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in
the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a
proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five
years is €1,140 million; the nominal value of payments estimated to be due after more than five years is €2,792 million.
[2] (b)The liabilities of Opella, which in 2022 and 2023 were presented in the relevant balance sheet line item for each class of liability, were reclassified in 2024 to Liabilities related to assets held for sale in accordance with IFRS 5 (see Note D.1.)